Humira biosimilar developers: can you find who's taking on AbbVie?
Over 30 companies are looking to compete against Abbvie in the adalimumab space. Can you find them all in our word search?
Amjevita was given the thumbs up by the Food and Drug Administration (FDA) in September, meaning Amgen could be the first to take a share of Humira’s $8.4bn US revenues once launched.
But Amgen is far from alone with its adalimumab biosimilar, as a report from PNS Pharma claims there are at least 33 versions in the clinical pipeline.
“More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years,” the report says.
So who are the companies looking to take on AbbVie? Well Biopharma-Reporter has laid them all out for you to find in our ‘Humira Biosimilar Word Search.’